
Claims:

1. A compound of formula (I) :



(I)

in which:

n is 0 or 1;


R1 is selected from the group consisting of: linear or branched C1-C5 alkyl optionally substituted by fluorine;

wherein said linear or branched C1-C5 alkyl optionally substituted by fluorine is selected from the group consisting of $-CH_2CF_3$ and $-CH_2$-isopropyl;

X is N or CH;

R2 is selected from the group consisting of: phenyl; phenyl substituted by linear or branched C1-C4 alkyl phenyl substituted by one or more substituent selected from Cl, F, CF_3, OCH_3 and OH; and a six-membered heterocycle comprising one, two or three nitrogen atoms;

wherein said heterocycle is selected from the group consisting of:



and .

2. The compound according to claim 1, wherein n is 1.

3. The compound according to claim 1 or 2, wherein R1 is $-CH_2CF_3$.

4. The compound according to claim 1, 2 or 3, wherein X is CH.

5. The compound according to any one of claims 1 to 4, wherein R1 is $-CH_2$-isopropyl.


6. The compound according to any one of claims 1 to 4, wherein R2 is phenyl.

7. The compound according to any one of claims 1 to 4, wherein R2 is phenyl substituted in meta position relative to the bond to X by a substituent selected from Cl, F, CF_3 and OCH_3.


8. The compound according to any one of claims 1 to 4, wherein R2 is phenyl substituted by fluorine.



















9. The compound according to any one of claims 1 to 4, wherein R2 is phenyl substituted by fluorine in para position relative to the bond to X.










10. The compound according to any one of claims 1 to 4, wherein R2 is selected from:


and

11. The compound according to claim 1, which is selected from the group consisting of:




,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

and

.

12. A compound according to any one of claims 1 to 11 for use as medicament.

13. A compound according to any one of claims 1 to 11 for use in the treatment of bacterial and mycobacterial infections.

14. A compound according to any one of claims 1 to 11 for use in the treatment of tuberculosis, leprosy and atypical mycobacterial infections.

15. A pharmaceutical composition comprising as active ingredient a compound according to any one of claims 1 to 11, and a pharmaceutically acceptable excipient.

16. The pharmaceutical composition of claim 15 further comprising an antibiotic active against bacteria and/or mycobacteria.

17. The pharmaceutical composition of claim 15 further comprising an antibiotic activatable via the EthA pathway.


18. The pharmaceutical composition of claim 15 further comprising an antibiotic selected from the thioamide family.

19. The pharmaceutical composition of claim 15 further comprising ethionamide or prothionamide.

20. A combination of a compound according to any one of claims 1 to 11 and of an antibiotic activatable via the EthA pathway for the manufacture of a medicament for the treatment of tuberculosis, leprosy and atypical mycobacterial infections.

Claims:

1. A compound of formula (I) :



(I)

in which:


n is 0 or 1;

R1 is $-CH_2CF_3$;

X is N or CH;

R2 is selected from the group consisting of: phenyl; phenyl substituted by linear or branched C1-C4 alkyl; phenyl substituted by one or more substituent selected from Cl, F, CF_3, OCH_3 and OH; and a six-membered heterocycle comprising one, two or three nitrogen atoms;

wherein said heterocycle is selected from the group consisting of:



and .

2. The compound according to claim 1, wherein n is 1.

3.. The compound according to claim 1 or 2, wherein X is CH.


4. The compound according to any one of claims 1 to 3, wherein R2 is phenyl.

5. The compound according to any one of claims 1 to 3, wherein R2 is phenyl substituted in meta position relative to the bond to X by a substituent selected from Cl, F, CF_3 and OCH_3.













6. The compound according to any one of claims 1 to 3, wherein R2 is phenyl substituted by fluorine.














7. The compound according to any one of claims 1 to 3, wherein R2 is phenyl substituted by fluorine in para position relative to the bond to X.


8. The compound according to any one of claims 1 to 3, wherein R2 is selected from:


and .

9. The compound according to claim 1, which is selected from the group consisting of:



,

,

,

,

,

,

,

,

,

,

,

.


,

,

,

,

,

,

,

,

,

,

,

,

,

, and

.

10. A compound according to any one of claims 1 to 9 for use as medicament.

11. A compound for use in the treatment of bacterial and mycobacterial infections, wherein said compound is a compound of formula (I) :



(I)

in which:

n is 0 or 1;


R1 is selected from the group consisting of: linear or branched C1-C5 alkyl optionally substituted by fluorine;

wherein said linear or branched C1-C5 alkyl optionally substituted by fluorine is selected from the group consisting of $-CH_2CF_3$ and $-CH_2$-isopropyl;

X is N or CH;


R2 is selected from the group consisting of: phenyl; phenyl substituted by linear or branched C1-C4 alkyl phenyl substituted by one or more substituent selected from Cl, F, CF_3, OCH_3 and OH; and a six-membered heterocycle comprising one, two or three nitrogen atoms;

wherein said heterocycle is selected from the group consisting of:



and .

12. A compound for use in the treatment of tuberculosis, leprosy and atypical mycobacterial infections, wherein said compound is a compound of formula (I) :



(I)

in which:

n is 0 or 1;


R1 is selected from the group consisting of: linear or branched C1-C5 alkyl optionally substituted by fluorine;

wherein said linear or branched C1-C5 alkyl optionally substituted by fluorine is selected from the group consisting of $-CH_2CF_3$ and $-CH_2$-isopropyl;

X is N or CH;


R2 is selected from the group consisting of: phenyl; phenyl substituted by linear or branched C1-C4 alkyl phenyl substituted by one or more substituent selected from Cl, F, CF_3, OCH_3 and OH; and a six-membered heterocycle comprising one, two or three nitrogen atoms;

wherein said heterocycle is selected from the group consisting of:



, , , and .

13. A pharmaceutical composition comprising as active ingredient a compound and a pharmaceutically acceptable excipient, wherein said compound is a compound of formula (I) :



(I)

in which:

n is 0 or 1;


R1 is selected from the group consisting of: linear or branched C1-C5 alkyl optionally substituted by fluorine;

wherein said linear or branched C1-C5 alkyl optionally substituted by fluorine is selected from the group consisting of $-CH_2CF_3$ and $-CH_2$-isopropyl;

X is N or CH;

R2 is selected from the group consisting of: phenyl; phenyl substituted by linear or branched C1-C4 alkyl phenyl substituted by one or more substituent selected from Cl, F, CF_3, OCH_3 and OH; and a six-membered heterocycle comprising one, two or three nitrogen atoms;

wherein said heterocycle is selected from the group consisting of:



, , , and .


14. The pharmaceutical composition of claim 13 further comprising an antibiotic active against bacteria and/or mycobacteria.

15. The pharmaceutical composition of claim 13 further comprising an antibiotic activatable via the EthA pathway.

16. The pharmaceutical composition of claim 13 further comprising an antibiotic selected from the thioamide family.

17. The pharmaceutical composition of claim 13 further comprising ethionamide or prothionamide.

18. The use of a combination of a compound and of an antibiotic activatable via the EthA pathway in the manufacture of a medicament for the treatment of tuberculosis, leprosy and atypical mycobacterial infections, wherein said compound is a compound of formula (I) :



(I)

in which:

n is 0 or 1;


R1 is selected from the group consisting of: linear or branched C1-C5 alkyl optionally substituted by fluorine;

wherein said linear or branched C1-C5 alkyl optionally substituted by fluorine is selected from the group consisting of $-CH_2CF_3$ and $-CH_2$-isopropyl;


X is N or CH;

R2 is selected from the group consisting of: phenyl; phenyl substituted by linear or branched C1-C4 alkyl phenyl substituted by one or more substituent selected from Cl, F, CF_3, OCH_3 and OH; and a six-membered heterocycle comprising one, two or three nitrogen atoms;

wherein said heterocycle is selected from the group consisting of:



19. The use of a compound of formula (I) :



(I)

in the manufacture of a medicament for the treatment of bacterial and mycobacterial infections in which:

n is 0 or 1;


R1 is selected from the group consisting of: linear or branched C1-C5 alkyl optionally substituted by fluorine;

wherein said linear or branched C1-C5 alkyl optionally substituted by fluorine is selected from the group consisting of $-CH_2CF_3$ and $-CH_2$-isopropyl;


X is N or CH;

R2 is selected from the group consisting of: phenyl; phenyl substituted by linear or branched C1-C4 alkyl phenyl substituted by one or more substituent selected from Cl, F, CF_3, OCH_3 and OH; and a six-membered heterocycle comprising one, two or three nitrogen atoms;

wherein said heterocycle is selected from the group consisting of:



20. The use of a compound of formula (I) :



(I)

in the manufacture of a medicament for the treatment of tuberculosis, leprosy and atypical mycobacterial infections in which:

n is 0 or 1;






R1 is selected from the group consisting of: linear or branched C1-C5 alkyl optionally substituted by fluorine;

wherein said linear or branched C1-C5 alkyl optionally substituted by fluorine is selected from the group consisting of $-CH_2CF_3$ and $-CH_2$-isopropyl;

X is N or CH;

R2 is selected from the group consisting of: phenyl; phenyl substituted by linear or branched C1-C4 alkyl phenyl substituted by one or more substituent selected from Cl, F, CF_3, OCH_3 and OH; and a six-membered heterocycle comprising one, two or three nitrogen atoms;

wherein said heterocycle is selected from the group consisting of:


, 
, 
, 
and 
.